No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .
The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial.
Although blockade of renin-angiotensin system have been cited as the first line of therapy for the management of diabetic nephropathy ( DN ) , however in a substantial number of patients , progression of renal disease are not completely halted by these agents . We have conducted a double blinded clinical trial to assess the additive effect of pentoxifylline on reduction of proteinuria among patients with type 2 DM under blockade of angiotensin system . The dosage of PTX used in our trial was at a low dosage of 400 mg daily and to our knowledge , we did not found article which evaluated the antiproteinuric effect of pentoxifylline in this dosage . One hundred patients with DN and persistent proteinuria despite treatment with losartan and enalapril in at least 3 months before inclusion in the study were r and omly assigned to two groups . Control group ( n=50 , 26 males and 24 females ) received losartan and enalapril , while treatment group ( PTX Group ) ( n=50 , 28 males and 22 females ) was given losartan , enalapril and pentoxifylline 400mg/day for 6 months . At the beginning of the study there were no significant differences in demographic and clinical characteristics of patients including serum creatinine , HbA1c , blood pressure and urinary protein excretion between two groups ( P>.05 ) . In the PTX group , the mean rate of urinary protein excretion have significantly decreased from 616.66 mg to 378.24 after 3 months ( P=.000 ) and to 192.05 mg after 6 months ( P=.000 ) whereas no significant changes were observed in the control group . The beneficial antiproteinuric effect of PTX was not associated to the degree of metabolic control and a reduction of blood pressure . In addition , at the end of study , the mean clearance of creatinine was significantly higher in PTX group ( P=.04 ) . In conclusion , PTX can significantly provide additive antiproteinuric effect and slow the decrease in GFR among patients with type 2 DM under blockade of angiotensin system
No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .